Dual antiplatelet therapy in patients with aspirin resistance following coronary artery bypass grafting: study protocol for a randomized controlled trial [NCT01159639]

摘要: Coronary artery disease remains the dominant cause of mortality in developed countries. While platelets have been recognized to play a pivotal role atherothrombosis, ideal antiplatelet regime after coronary surgery elusive. The evolution CABG has presently moved beyond technical improvements involve modulation pharmacologic management designed improve patient outcomes. aim this trial will be test hypothesis that addition clopidogrel patients with documented postoperative aspirin resistance reduce incidence major cardiovascular events. Patients scheduled for isolated eligible study. whom multiple electrode aggregometry documents randomized into two groups. control group receive 300 mg aspirin. dual 75 followed 6 months. Major adverse cardiac and cerebrovascular events (death from any cause, myocardial infarction, stroke, hospitalization due pathology) as well bleeding recorded. This first specifically address issue therapy undergoing who found resistant. In event proves beneficial subset surgical patients, study could significantly impact their future management. controlled registered at ClinicalTrials.gov website (Identifier NCT01159639).